Alcon AG

Alcon AG

39.88
BRL
+1.04
(+2.68%)
0.68EPS
55.38P/E
188.92BMarket Cap
Mar 02Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.3
1.33
1.41
1.48
1.34
1.63
1.7
1.84
1.93
2.03
2.17
Basic EPS, GAAP
-0.03
0.05
-0.04
-0.13
-0.1
0.07
0.07
0.19
0.2
0.19
0.13
Free Cash Flow per Basic Share
0.15
0.14
0.08
0.05
0.05
0.03
0.09
0.1
0.27
0.31
0.33
Dividend per Share
- -
- -
- -
- -
- -
0.01
0.02
0.02
0.03
0.03
- -
Book Value per Share
- -
4.53
4.45
3.8
3.7
3.77
3.86
4.02
4.19
4.34
4.34
Tangible Book Value per Share
- -
0.51
0.6
0.03
0.16
0.31
0.21
0.51
0.78
0.74
0.87
Basic Weighted Avg Shares
5,088
5,088
5,088
5,083
5,092
5,102
5,116
5,133
5,148
5,135
5,061
Sales/Revenue/Turnover
6,596
6,792
7,153
7,508
6,833
8,291
8,717
9,455
9,911
10,401
10,984
Operating Margin (%)
0.15
-1.13
-3.47
-2.49
-7.05
7
7.71
10.99
14.26
13.08
9.08
Depreciation Expense
1,289
1,305
1,622
1,425
1,623
1,219
1,123
1,221
1,228
1,335
1,887
Net Income, GAAP
-170
256
-227
-656
-531
376
335
974
1,018
980
666
Effective Tax Rate (%)
- -
- -
- -
- -
- -
10.05
27.65
- -
18.95
15.52
15.27
Profit Margin (%)
-2.58
3.77
-3.17
-8.74
-7.77
4.54
3.84
10.3
10.27
9.42
6.06
Working Capital
- -
1,509
1,506
1,936
2,729
2,914
2,455
3,249
4,031
3,400
4,180
LT Debt
- -
84
89
3,498
4,264
4,305
4,900
5,011
4,967
4,591
5,184
Total Equity
- -
23,029
22,639
19,303
18,822
19,256
19,677
20,624
21,553
22,035
21,734
Return on Invested Capital (%)
- -
- -
- -
- -
- -
2.2
1.99
- -
4.35
4.23
3.08
Return on Capital (%)
- -
- -
- -
- -
- -
2.06
1.78
- -
4.48
4.27
3.1
Return on Common Equity (%)
- -
- -
-0.99
-3.13
-2.79
1.97
1.72
4.83
4.83
4.5
3.04

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
648
648
147
LT Borrowings
4,157
4,149
4,689
LT Finance Leases
448
499
495
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5,078
5,033
5,002
Market Capitalization
37,495
33,239
36,453

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
6,620
6,624
6,974
Cash, Cash Equivalents & STI
1,659
1,456
1,807
Accounts Receivable, Net
1,981
2,079
2,048
Inventories
2,438
2,510
2,569
Total Current Liabilities
3,004
3,167
2,794
Payables & Accruals
1,127
1,196
1,246
ST Debt
648
648
147
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
3.21%
2.24%
Free Cash Flow
- -
68.12%
14.29%
Net Income, GAAP
- -
1.97%
-3.73%
Sales/Revenue/Turnover
- -
8.94%
4.94%
Total Cash Common Dividend
- -
- -
27.69%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,459
2,496
2,454
2,502
9,911
2025
2,473
2,596
2,614
2,718
10,401
2026
2,706
2,823
2,737
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.04
0.05
0.06
0.2
2025
0.07
0.03
0.05
0.04
0.19
2026
0.04
- -
0.05
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.03
2025
- -
- -
- -
- -
0.03
2026
- -
- -
- -
- -
- -

Company Description

CEO
David J. Endicott
Full Time Employees
25,942
Sector
Health technology
Industry
Medical specialties
Address
Chemin de Blandonnet 8 Geneva GE Switzerland 1214
IPO Date
Apr 9, 2019
Website
alcon.com
Business
Alcon Inc. (ALC.SW) researches, develops, manufactures, distributes and sells eye care products worldwide, operating in two primary segments, Surgical and Vision Care; the Surgical segment provides equipment, instrumentation and diagnostics such as the Centurion vision system and LenSx laser system, intraocular lenses including PanOptix, Vivity and AcrySof IQ, other implantables, consumables like viscoelastics, surgical solutions, incisional instruments and custom packs for cataract, vitreoretinal and refractive surgeries; the Vision Care segment offers daily disposable, reusable and color-enhancing contact lenses under brands like Dailies, Total1, Precision1 and Air Optix, plus ocular health products including Systane dry eye drops, Pataday allergy relief, contact lens care solutions, ocular vitamins and redness relievers. Founded in 1945 in Fort Worth, Texas, by pharmacists Robert Alexander and William Conner, the company is incorporated in Fribourg, Switzerland, with global headquarters in Geneva and a major operational hub in Fort Worth; it employs over 25,000 associates, operates in 60 countries and serves patients in more than 140 countries. In recent developments, Alcon acquired a majority interest in Aurion Biotech in March 2025 to advance cell therapy AURN001 for corneal endothelial disease into Phase 3 trials, agreed to acquire LENSAR in March 2025 for its ALLY Robotic Cataract Laser System and Streamline software to bolster femtosecond laser-assisted cataract surgery, entered a definitive agreement in August 2025 to purchase STAAR Surgical for approximately $1.5 billion to add EVO implantable collamer lenses for myopia correction, and plans to acquire LumiThera for its photobiomodulation device targeting dry age-related macular degeneration, with most transactions expected to close in mid-to-late 2025.

Company News

  • Alcon: 3 Key Takeaways for Long-Term Investors

  • Alcon Inc. (ALC) Q3 2026 Earnings Call Transcript

  • ALC's Q3 Earnings Beat, Revenues Miss, '26 Outlook Narrows, Stock Down

  • Alcon shares fall as tighter eye-care market outlook raises growth concerns

  • Alcon (ALC) Reports Q3 Earnings: What Key Metrics Have to Say

  • Innovation and Product Launch Momentum Drive Alcon's Third-Quarter 2026 Growth

  • Algoma Central Corporation Announces Closing of Over-Allotment Option of Additional Debentures

  • Algoma Central Corporation Reports Financial Results for the 2026 Third Quarter

  • Countdown to Alcon (ALC) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

  • Alcon (ALC) Surges 6.8%: Is This an Indication of Further Gains?

  • Higher Margins, Better ROIC And Capable Management Define Pershing Square's Q3 2026 Portfolio

  • Alcon Sees Another Bullish Rating After Clear Portfolio Growth Direction In Eyecare

  • Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2

  • Algoma Central Corporation Announces $62.5 million Offering of 6.20% Convertible Unsecured Subordinated Debentures

  • FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

  • FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes

  • Credo Expands AI Connectivity Portfolio With 1.6T ZeroFlap ALC

  • Credo Unveils 1.6T ZeroFlap Active Light Cable, Industry's First Row-Scale, Wide-Parallel Optical Interconnect for AI Data Centers

  • Algoma Central (TSE:ALC) Shares Cross Above 50 Day Moving Average – Here’s Why

  • Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?